UPDATE: Sterne Agee Resumes MedAssets at Buy on Improving Profitability
In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on MedAssets (NASDAQ: MDAS) with a Buy rating and $24.00 price target.
In the report, Sterne Agee noted, “We see profitability improving substantially as the company's GPO business continues to dominate market share and adoption of RCM IT applications improves following hospitals' race to achieve initial requirements under the CMS EHR incentive program. Re-initiate coverage with Buy rating and $24 price target.”
MedAssets closed on Tuesday at $17.31.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.